A detailed history of Royal London Asset Management LTD transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Royal London Asset Management LTD holds 77,345 shares of BMRN stock, worth $4.91 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
77,345
Previous 73,287 5.54%
Holding current value
$4.91 Million
Previous $6.03 Million 9.9%
% of portfolio
0.01%
Previous 0.02%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$69.02 - $93.84 $280,083 - $380,802
4,058 Added 5.54%
77,345 $5.44 Million
Q2 2024

Aug 07, 2024

BUY
$74.43 - $92.22 $81,128 - $100,519
1,090 Added 1.51%
73,287 $6.03 Million
Q1 2024

May 14, 2024

SELL
$83.81 - $99.0 $135,772 - $160,380
-1,620 Reduced 2.19%
72,197 $6.31 Million
Q4 2023

Feb 13, 2024

BUY
$76.22 - $98.51 $146,113 - $188,843
1,917 Added 2.67%
73,817 $7.12 Million
Q3 2023

Nov 14, 2023

BUY
$85.07 - $94.48 $308,293 - $342,395
3,624 Added 5.31%
71,900 $6.36 Million
Q2 2023

Aug 11, 2023

BUY
$86.68 - $100.3 $471,885 - $546,033
5,444 Added 8.66%
68,276 $5.92 Million
Q1 2023

May 15, 2023

SELL
$87.74 - $117.27 $93,881 - $125,478
-1,070 Reduced 1.67%
62,832 $6.11 Million
Q3 2022

Nov 14, 2022

SELL
$82.16 - $96.94 $22,758 - $26,852
-277 Reduced 0.43%
63,902 $5.42 Million
Q2 2022

Aug 12, 2022

SELL
$71.48 - $86.85 $8,649 - $10,508
-121 Reduced 0.19%
64,179 $5.32 Million
Q1 2022

May 13, 2022

BUY
$74.28 - $92.69 $267,185 - $333,405
3,597 Added 5.93%
64,300 $4.96 Million
Q4 2021

Oct 18, 2022

SELL
$71.72 - $91.47 $151,974 - $193,824
-2,119 Reduced 3.37%
60,703 $5.37 Million
Q4 2021

Jan 18, 2022

SELL
$71.72 - $91.47 $151,974 - $193,824
-2,119 Reduced 3.37%
60,703 $5.37 Million
Q3 2021

Oct 18, 2022

SELL
$74.77 - $85.47 $155,372 - $177,606
-2,078 Reduced 3.2%
62,822 $4.86 Million
Q3 2021

Nov 02, 2021

SELL
$74.77 - $85.47 $155,372 - $177,606
-2,078 Reduced 3.2%
62,822 $4.86 Million
Q2 2021

Oct 18, 2022

BUY
$75.51 - $84.79 $54,442 - $61,133
721 Added 1.12%
64,900 $5.42 Million
Q1 2021

Oct 17, 2022

BUY
$74.73 - $90.69 $53,880 - $65,387
721 Added 1.12%
64,900 $4.9 Million
Q4 2020

Jan 29, 2021

SELL
$72.61 - $90.2 $26,066 - $32,381
-359 Reduced 0.55%
64,900 $5.69 Million
Q3 2020

Nov 04, 2020

SELL
$71.87 - $131.03 $1,868 - $3,406
-26 Reduced 0.04%
65,259 $4.96 Million
Q2 2020

Jul 31, 2020

SELL
$79.55 - $124.22 $336,178 - $524,953
-4,226 Reduced 6.08%
65,285 $7.98 Million
Q3 2019

Nov 12, 2019

SELL
$67.4 - $85.11 $54,054 - $68,258
-802 Reduced 1.14%
69,511 $4.69 Million
Q1 2019

Apr 30, 2019

SELL
$84.2 - $98.62 $537,111 - $629,096
-6,379 Reduced 8.32%
70,313 $0
Q4 2018

Jan 29, 2019

BUY
$80.14 - $106.07 $388,037 - $513,590
4,842 Added 6.74%
76,692 $6.41 Million
Q3 2018

Nov 08, 2018

SELL
$93.92 - $105.72 $31,557 - $35,521
-336 Reduced 0.47%
71,850 $0
Q2 2018

Sep 19, 2018

BUY
$76.01 - $99.03 $5.49 Million - $7.15 Million
72,186 New
72,186 $6.8 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $11.8B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Royal London Asset Management LTD Portfolio

Follow Royal London Asset Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal London Asset Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Royal London Asset Management LTD with notifications on news.